Skip to main content
Journal ArticleOPEN ACCESS

First-Line Chemotherapy for HER-2–Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment

  • Morabito A
  • Piccirillo M
  • et al.
The Oncologist (2007) 12(11) 1288-1298
DOI: 10.1634/theoncologist.12-11-1288
10Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

After completing this course, the reader will be able to: Discuss the value of retreatment with anthracyclines for HER-2–negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment.Discuss the role of liposomal anthracyclines, taxanes, and combinations without anthracyclines and taxanes, or innovative treatments, including target-based agents.Comment on the weakness and quality of available evidence.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Cite

CITATION STYLE

APA

Morabito, A., Piccirillo, M. C., Monaco, K., Pacilio, C., Nuzzo, F., … Perrone, F. (2007). First-Line Chemotherapy for HER-2–Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment. The Oncologist, 12(11), 1288–1298. https://doi.org/10.1634/theoncologist.12-11-1288

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free